SynDevRx
Manufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1 Broadway Ste 14, Cambridge, Massachuse...Phone Number
(617) 401-3110Website
www.syndevrx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About SynDevRx
SynDevRx is a pioneering company in the field of Metabo-Oncology, focusing on transforming cancer treatment by targeting the metabolic drivers and angiogenic factors that contribute to cancer progression. Their lead compound, Evexomostat, is designed to treat cancer patients with metabolic complications and enhances the effectiveness of existing therapies. The company is currently validating its innovative approach through clinical trials, particularly in breast and prostate cancers, aiming to improve patient outcomes. SynDevRx's mission is to address the needs of an under-treated patient population across various solid tumor types.Explore more
SynDevRx Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is SynDevRx your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if SynDevRx had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at SynDevRx
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on SynDevRx recently announced quarterly report
Product Launch: Get notified when SynDevRx launches new products
Funding: Get notified immidiatlly once SynDevRx has new funding data
Check out if SynDevRx is spiking on competitors!
Check if SynDevRx has recently received funding, and reach out quickly before it becomes old news!
SynDevRx, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to SynDevRx
Compare insights from companies similar to SynDevRx, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
SynDevRx is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
SynDevRx is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about SynDevRx.
SynDevRx financials insights
Gather financial insights about SynDevRx, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2009
Unspecified
$569K
2012
Debt
$16.3M
2017
Debt
$1.5M
SynDevRx Tech Stack
A closer look at the technologies used by SynDevRx
SynDevRx News & Media
SynDevRx Publishes Data On Evexomostat Establishing New Metabo-Oncology Therapeutic Modality
Frontiers in Oncology publication positions metabo-oncology as a differentiated platform for pharma and a novel, risk-mitigated opportunity for investors. CAMBRIDGE, MA, UNITED STATES, February 19, 2026 /EINPresswire.com/ -- SynDevRx, Inc., a clinical- …Memorial Sloan Kettering to Present Clinical Data from The ARETHA-1 Trial of SynDevRx’s Evexomostat in mTNBC at SABCS
Safety Run-in Cohort Results Show Anti-tumor Activity Plus Systemic Metabolic Improvements with Evexomostat Plus Eribulin in Late-line Metastatic TNBC Patients NEW YORK, NY, UNITED STATES, December 2, 2025 /EINPresswire.com/ -- Memorial Sloan Kettering …$1.2M Grant Awarded for Groundbreaking Prostate Cancer Research on SynDevRx MetAP2 Inhibitor 'Evexomostat'
Award follows extensive pre-clinical, single agent activity data generated by Prof. Colleen Nelson’s lab at QUT in ‘Aggressive Variant’ prostate cancer models CAMBRIDGE, MA, UNITED STATES, January 9, 2025 /EINPresswire.com/ -- Cambridge, MA (USA) and …First Patient Treated in Innovative Clinical Study 'Amelia-1', Testing the Novel Investigational Drug Evexomostat Plus a PI3K Inhibitor in Late-Stage Breast Cancer Patients
Amelia™-1 Study is testing if evexomostat can improve patients' safety and clinical response to a PI3K inhibitor plus an estrogen receptor degrader. Evexomostat, a novel MetAP2 inhibitor, controlled PI3K-induced hyperglycemia in the first study patient, consistent with pre-clinical data. Further, ctDNA data shows no evidence of residual PIK3CA mutation in blood after 6 weeks of treatment.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding SynDevRx
Sign Up For FreeTo access detailed company insights
SynDevRx is a pioneering company in the field of Metabo-Oncology, focusing on transforming cancer treatment by targeting the metabolic drivers and angiogenic factors that contribute to cancer progression. Their lead compound, Evexomostat, is designed to treat cancer patients with metabolic complications and enhances the effectiveness of existing th... Read More
